论文部分内容阅读
目的:探究分析血清SCCA、CA19-9和CA125水平联合检测在宫颈癌临床诊断中所发挥的临床价值。方法:选择2013年6月至2015年6月,该院收治的70例宫颈癌患者为观察对象,设为观察组;另选同期来我院进行体检的70例女性健康体检者,设为对照组。两组分别接受血清肿瘤标志物SCCA、CA19-9和CA125水平检测,对比两组人员在结果数据上的差异。结果:观察组患者的血清中的SCCA、CA19-9和CA125水平要显著高于对照组的健康体检者。结论:血清SCCA、CA19-9和CA125水平联合检测在宫颈癌临床诊断具有突出的临床价值,应在临床诊疗工作中加以重视。
Objective: To explore the clinical value of combined detection of serum SCCA, CA19-9 and CA125 levels in the clinical diagnosis of cervical cancer. Methods: From June 2013 to June 2015, 70 cases of cervical cancer patients treated in this hospital were selected as the observation group and selected as the observation group. In the same period, 70 cases of female physical examination in our hospital were selected as the control group group. Two groups received serum tumor markers SCCA, CA19-9 and CA125 levels were compared between the two groups of people in the data on the differences. Results: The levels of SCCA, CA19-9 and CA125 in the observation group were significantly higher than those in the control group. Conclusion: The combined detection of serum SCCA, CA19-9 and CA125 levels has prominent clinical value in the clinical diagnosis of cervical cancer and should be paid more attention in clinical diagnosis and treatment.